Business
Add as a preferred source on GoogleSkyrizi and Rinvoq are expected to support the quarter, and the estimate is more than twice the year-earlier level.
Analysts expect Skyrizi and Rinvoq to support AbbVie’s third-quarter results, due before U.S. markets open Friday, Oct. 30, with earnings forecast at $3.77 per share.
AbbVie has yet to release the quarter’s actual results; the $3.77-per-share amount remains an analyst projection. That estimate is more than twice the year-earlier level.
Revenue increased 6% to $1.415 billion, and the company maintained its fiscal 2027 sales and earnings outlook.
Basic earnings per share under IFRS were ¥95.60 for the six months ended Sept. 30, 2026.
The six-month total was a record. Higher Parts and Service revenue and yen depreciation supported adjusted operating income as logistics costs rose.
